Enhertu Phase 3 Trial for Lung Cancer Begins
🕓 Estimated Reading Time: 5 minutes Overview In a significant development for oncology, a new Phase 3 clinical study, dubbed DESTINY-Lung06, has officially commenced. This pivotal trial is set to investigate Enhertu (trastuzumab deruxtecan) as a potential first-line therapy for patients suffering from unresectable, advanced or metastatic non-small cell lung cancer (NSCLC) characterized by HER2 overexpression. The initiation of this study marks a crucial step forward in exploring new avenues for lung cancer treatment , offering a ray of hope for a patient population with limited therapeutic options. Background & Context Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases, making it one of the most prevalent and challenging cancers globally. While advancements in targeted therapies and immunotherapies have transformed treatment paradigms for many patients, those with specific molecular markers, such as HER2 overexpression, still face significant unmet...